GSK3B and Alzheimer disease: 2022). In terms of glucose metabolism, IRS1 and GSK3β are key targets in the insulin signaling pathway. To verify the pathological properties of this model related to central glucose metabolism in AD, we used immunohistochemistry. IRS1‐positive staining increased in the AD group compared to that in the control group, and positive staining decreased after DSS intervention (Figure 7). The area of GSK3β‐positive staining in the AD group was increased compared to that in the control group, and DSS intervention decreased its expression (Figure 7).